Global Vaccine Market

1 INTRODUCTION OF GLOBAL VACCINE MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VACCINE MARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL VACCINE MARKET, BY TYPE
5.1 Overview
5.2 Monovalent
5.3 Multivalent

6 GLOBAL VACCINE MARKET, BY TECHNOLOGY
6.1 Overview
6.2 Conjugate Vaccines
6.3 Inactivated and Subunit Vaccines
6.4 Live Attenuated Vaccines
6.5 Recombinant Vaccines
6.6 Toxoid Vaccines

7 GLOBAL VACCINE MARKET, BY PATH OF ADMINISTRATION
7.1 Overview
7.2 Intramuscular and Subcutaneous Administration
7.3 Oral Administration
7.4 Others

8 GLOBAL VACCINE MARKET, BY DISEASE INDICATION
8.1 Overview
8.2 Pneumococcal Disease
8.3 DTP
8.4 Influenza
8.5 Human Papilloma Virus
8.6 Meningococcal Disease
8.7 Polio
8.8 Rotavirus
8.9 Hepatitis
8.10 MMR
8.11 Varicella
8.12 Dengue
8.13 Others

9 GLOBAL VACCINE MARKET, BY PATH OF END USER
9.1 Overview
9.2 Pediatrics
9.3 Adults
9.4 Veterinary Practices (Animals)

10 GLOBAL VACCINE MARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL VACCINE MARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Pfizer, Inc.
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Glaxosmithkline PLC.
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Merck & Co., Inc.
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Sanofi Pasteur SA
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 CSL Limited
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Emergent Biosolutions, Inc.
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Johnson & Johnson
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Medimmune, LLC
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 AstellasPharma, Inc.
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Developments

12.10 Bavarian Nordic
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Developments

12.11 Mitsubishi Tanabe Pharma Corporation
12.11.1 Overview
12.11.2 Financial Performance
12.11.3 Product Outlook
12.11.4 Key Developments

12.12 Daiichi Sankyo Company, Limited
12.12.1 Overview
12.12.2 Financial Performance
12.12.3 Product Outlook
12.12.4 Key Developments

12.13 Protein Sciences Corporation
12.13.1 Overview
12.13.2 Financial Performance
12.13.3 Product Outlook
12.13.4 Key Developments

12.14 Panacea Biotec
12.14.1 Overview
12.14.2 Financial Performance
12.14.3 Product Outlook
12.14.4 Key Developments

12.15 Serum Institute of India
12.15.1 Overview
12.15.2 Financial Performance
12.15.3 Product Outlook
12.15.4 Key Developments

13 Appendix
13.1 Related Reports